Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherRevenue - Other
Ratios

Perspective Therapeutics (CATX) Accumulated Depreciation & Amortization (2016 - 2025)

Perspective Therapeutics' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $4.4 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $4.4 million; the TTM value through Jun 2025 reached $4.4 million, changed N/A, while the annual FY2024 figure was $3.0 million, 342.45% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2025 was $4.4 million at Perspective Therapeutics, up from $3.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.3 million in Q3 2023 and bottomed at -$1.3 million in Q4 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $7.2 million (2021), against an average of $5.0 million.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 342.45% in 2024 against a maximum downside of 87.01% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $7.3 million in 2021, then plummeted by 117.77% to -$1.3 million in 2022, then skyrocketed by 151.54% to $669000.0 in 2023, then skyrocketed by 342.45% to $3.0 million in 2024, then soared by 49.39% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Accumulated Depreciation & Amortization are $4.4 million (Q2 2025), $3.7 million (Q1 2025), and $3.0 million (Q4 2024).